Grifola frondosa (Maitake mushroom) water extract inhibits vascular endothelial growth factor-induced angiogenesis through inhibition of reactive oxygen species and extracellular signal-regulated kinase phosphorylation

Journal of Medicinal Food

Volumn 11, Issue 4, 2008, Pages 643-651

  Lee, Jong Suk ^a   Park, Byung Chul ^a   Ko, Yu Jin ^a   Choi, Mi Kyoung ^a   Choi, Han Gon ^a   Yong, Chul Soon ^a   Lee, Jae Sung ^a   Kim, Jung Ae ^a  

^a Yeungnam University   (South Korea)

Author keywords

Angiogenesis; Extracellular signal regulated kinase; Grifola frondosa fruiting body; Reactive oxygen species; Vascular endothelial growth factor

Indexed keywords

GRIFOLA FRONDOSA EXTRACT; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLANT EXTRACT; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; WATER;

ANGIOGENESIS; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; CHICK; CHORIOALLANTOIS; CONCENTRATION RESPONSE; DOSE RESPONSE; ENDOTHELIUM CELL; FRUITING BODY; HUMAN; HUMAN CELL; HUMAN UMBILICAL VEIN ENDOTHELIAL CELL; IN VIVO STUDY; INHIBITION KINETICS; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; UMBILICAL VEIN;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIOXIDANTS; CELL CULTURE TECHNIQUES; CHICK EMBRYO; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FRUITING BODIES, FUNGAL; GRIFOLA; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PHYTOTHERAPY; PLANT EXTRACTS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

BASIDIOMYCOTA; GRIFOLA FRONDOSA;

EID: 57349118749     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2007.0629     Document Type: Article

References (57)

1. Mizuno T, Zhuang C: Maitake, Grifola frodosa: pharmacological effects. Food Rev Int 1995;11:135-149.
2. Kabir Y, Yamaguchi M, Kimura S: Effect of shiitake (Lentinus edodes) and maitake (Grifola frondosa) mushrooms on blood pressure and plasma lipids of spontaneously hypertensive rats. J Nutr Sci Vitaminol (Tokyo) 1987;33:341-346.
3. Kabir Y, Kimura S: Dietary mushrooms reduce blood pressure in spontaneously hypertensive rats (SHR). J Nutr Sci Vitaminol (Tokyo) 1989;35:91-94.
4. Ohtsuru M, Horio H, Masui H, Takeda I: Effects of administration of Grifola frondosa on blood pressure and body weight in spontaneously hypertensive rats. Nippon Shokuhin Kagaku Kogaku Kaishi 1999;46:806-814.
5. Kubo K, Aoki H, Nanba H: Anti-diabetic activity present in the fruit body of Grifola frondosa (maitake). Biol Pharm Bull 1994;17:1106-1110.
6. Kubo K, Nanba H: Anti-hyperliposis effect of maitake fruit body (Grifola frondosa). Biol Pharm Bull 1997;20:781-785.
7. Kubo K, Nanba H: Modification of cellular immune responses in experimental autoimmune hepatitis in mice by maitake (Grifola frondosa). Mycoscience 1998;39:351-360.
8. Kodama N, Harada N, Nanba H: A polysaccharide, extract from Grifola frondosa, induces Th-1 dominant responses in carcinoma-bearing BALB/C mice. Jpn J Pharmacol 2002;90:357-360.
9. Kurashige S, Akazawa Y, Endo F: Effects of Lentinus edodes, Grifola frondosa and Pleurotus ostreatus administration on cancer outbreak, and activities of macrophages and lymphocytes in mice treated with a carcinogen, N-butyl-N-butanolnitrosoamine. Immunopharmacol Immunotoxicol 1997;19:175-183.
10. Ohno N, Adachi Y, Suzuki I, Sato K, Oikawa S, Yadomae T: Characterization of the antitumor glucan obtained from liquid-cultured Grifola frondosa. Chem Pharm Bull 1986;34:1709-1715.
11. Shigesue K, Kodama N, Nanba H: Effects of maitake (Grifola frondosa) polysaccharide on collagen-induced arthritis in mice. Jpn J Pharmacol 2000;84:293-300.
12. Suzuki I, Hashimoto K, Oikawa S, Sato K, Osawa M, Yadomae T: Antitumor and immunomodulating activities of a β-glucan obtained from liquid cultured Grifola frondosa. Chem Pharm Bull 1989;37:410-413.
13. Bussolino F, Mantovani A, Persico G: Molecular mechanisms of blood vessel formation. Trends Biochem Sci 1997;22:251-256.
14. Naldini A, Carraro F: Role of inflammatory mediators in angiogenesis. Curr Drug Targets Inflamm Allergy 2005;4:3-8.
15. Ren G, Michael LH, Entman ML, Frangogiannis NG: Morphological characteristics of the microvasculature in healing myocardial infarcts. J Histochem Cytochem 2002;50:71-79.
16. Szekanecz Z, Koch AE: Endothelial cells in inflammation and angiogenesis. Curr Drug Targets Inflamm Allergy 2005;4:319-323.
17. Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM, Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 1997;79:233-269.
18. Cao R, Eriksson A, Kubo H, Alitalo K, Cao Y, Thyberg J: Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ Res 2004;94:664-670.
19. Carmeliet P, Collen D: Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development. Curr Top Microbiol Immunol 1999;237:133-158.
20. Ferrara N: Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002;29:10-14.
21. Kroll J, Waltenberger J: The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem 1997;272:32521-32527.
22. Colavitti R, Pani G, Bedogni B, Anzevino R, Borrello S, Waltenberger J, Galeotti T: Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR. J Biol Chem 2002;277:3101-3108.
23. Matsumoto T, Claesson-Welsh L: VEGF receptor signal transduction. Sci STKE 2001;2001:RE21.
24. Griendling KK, Sorescu D, Ushio-Fukai M: NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000;86:494-501.
25. Lelkes PI, Hahn KL, Sukovich DA, Karmiol S, Schmidt DH: On the possible role of reactive oxygen species in angiogenesis. Adv Exp Med Biol 1998;454:295-310.
26. Maulik N, Das DK: Redox signaling in vascular angiogenesis. Free Radic Biol Med 2002;33:1047-1060.
27. Babior BM: The NADPH oxidase of endothelial cells. IUBMB Life 2000;50:267-269.
28. Abid MR, Kachra Z, Spokes KC, Aird WC: NADPH oxidase activity is required for endothelial cell proliferation and migration. FEBS Lett 2000;15:252-256.
29. Chen JX, Zeng H, Lawrence ML, Blackwell TS, Meyrick B: Angiopoietin-1-induced angiogenesis is modulated by endothelial NADPH oxidase. Am J Physiol Heart Circ Physiol 2006;291:H1563-H1572.
30. Chen JX, Zeng H, Tuo QH, Yu H, Meyrick B, Aschner JL: NADPH oxidase modulates myocardial Akt, ERK1/2 activation, and angiogenesis after hypoxia-reoxygenation. Am J Physiol Heart Circ Physiol 2007;292:H1664-H1674.
31. th ed. Association of Official Analytical Chemists, Arlington, VA, 1995.
32. Singleton VL, Orthofer R, Lamuela-Raventos RM: Analysis of total phenols and other oxidation substrates and antioxidants by means of Folin-Ciocalteu reagent. Methods Enzymol 1999;299:152-178.
33. Auerbach R, Kubai L, Knighton D, Folkman J: A simple procedure for the long-term cultivation of chicken embryos. Dev Biol 1974;41:391-394.
34. Colman RW, Pixley RA, Sainz IM, Song JS, Isordia-Salas I, Muhamed SN, Powell JA, Mousa SA: Inhibition of angiogenesis by antibody blocking the action of proangiogenic high-molecular-weight kininogen. J Thromb Haemost 2003;1:164-170.
35. Kim MS, Lee EJ, Choi HR, Moon A: p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast cancer cells. Cancer Res 2003;63:5454-5461.
36. 2-M cell fraction and inhibition of matrigel invasion, may predict in vivo-selective antimetastasis activity of ruthenium complexes. J Pharmacol Exp Ther 2000;295:927-933.
37. Yoshimoto K, Nishizawa S, Koshino H, Sato Y, Teramae N, Maeda M: Assignment of hydrogen-bond structure in a ligand-nucleobase complex inside duplex DNA: combined use of quantum chemical calculations and 15N NMR experiments. Nucleic Acids Symp Ser (Oxf) 2005;49:255-256.
38. Belloni D, Scabini S, Foglieni C, Veschini L, Giazzon A, Colombo B, Fulgenzi A, Helle KB, Ferrero ME, Corti A, Ferrero E: The vasostatin-I fragment of chromogranin A inhibits VEGF-induced endothelial cell proliferation and migration. FASEB J 2007;21:3052-3062.
39. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH: Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994;269:26988-26995.
40. Cai J, Jiang WG, Ahmed A, Boulton M: Vascular endothelial growth factor-induced endothelial cell proliferation is regulated by interaction between VEGFR-2, SH-PTP1 and eNOS. Microvasc Res 2006;71:20-31.
41. Ushio-Fukai M, Tang Y, Fukai T, Dikalov SI, Ma Y, Fujimoto M, Quinn MT, Pagano PJ, Johnson C, Alexander RW: Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res 2002;91:1160-1167.
42. Mayell M: Maitake extracts and their therapeutic potential. Altern Med Rev 2001;6:48-60.
43. Matsui K, Kodama N, Nanba H: Effects of maitake (Grifola frondosa) D-fraction on the carcinoma angiogenesis. Cancer Lett 2001;172:193-198.
44. Folkman J: Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972;175:409-416.
45. Hillen F, Griffioen AW: Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastas Rev 2007;26:489-502.
46. Walsh DA, Pearson CI: Angiogenesis in the pathogenesis of inflammatory joint and lung diseases. Arthritis Res 2001;3:147-153.
47. Bonnet CS, Walsh DA: Osteoarthritis, angiogenesis and inflammation. Rheumatology (Oxford) 2005;44:7-16.
48. Clavel G, Bessis N, Lemeiter D, Fardellone P, Mejjad O, Menard JF, Pouplin S, Boumier P, Vittecoq O, Le Loet X, Boissier MC: Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction. Clin Immunol 2007;124:158-164.
49. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
50. Ray BK, Shakya A, Ray A: Vascular endothelial growth factor expression in arthritic joint is regulated by SAF-1 transcription factor. J Immunol 2007;178:1774-1782.
51. Wilkinson-Berka JL: Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycloxygenase-2 and nitric oxide. Curr Pharm Des 2004;10:3331-3348.
52. Decoursey TE, Ligeti E: Regulation and termination of NADPH oxidase activity. Cell Mol Life Sci 2005;62:2173-2193.
53. Shankar S, Ganapathy S, Srivastava RK: Green tea polyphenols: biology and therapeutic implications in cancer. Front Biosci 2007;12:4881-4899.
54. Lamy S, Gingras D, Beliveau R: Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. Cancer Res 2002;62:381-385.
55. Fukuda S, Kaga S, Zhan L, Bagchi D, Das DK, Bertelli A, Maulik N: Resveratrol ameliorates myocardial damage by inducing vascular endothelial growth factor-angiogenesis and tyrosine kinase receptor Flk-1. Cell Biochem Biophys 2006;44:43-49.
56. Labrecque L, Lamy S, Chapus A, Mihoubi S, Durocher Y, Cass B, Bojanowski MW, Gingras D, Beliveau R: Combined inhibition of PDGF and VEGF receptors by ellagic acid, a dietary-derived phenolic compound. Carcinogenesis 2005;26:821-826.
57. Neuhaus TS, Pabst S, Stier AA, Weber K, Schror A, Sachinidis H, Vetter H, Ko YD: Inhibition of the vascular-endothelial growth factor-induced intracellular signaling and mitogenesis of human endothelial cells by epigallocatechin-3 gallate. Eur J Pharmacol 2004;483:223-227.